A Longitudinal Study of Group A Streptococcal Colonization and Pharyngitis in US Children.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
medline:
27
11
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
ppublish
Résumé
Group A streptococci (GAS) are a major cause of pharyngitis in children. Recently, there were severe GAS outbreaks. The aims of this study were to assess pharyngeal colonization prevalence in healthy children, to assess different diagnostic definitions for GAS pharyngitis and to estimate incidence rates for these infections. A 2-year longitudinal study was conducted in healthy children in the United States. Pharyngeal swabs were cultured every 3 months for GAS colonization. Serum antistreptolysin O, antideoxyribonuclease B (DNaseB) and antistreptococcal C5a peptidase (SCP) antibody titers were assessed at baseline. When participants developed a sore throat, pharyngeal swabs were collected for rapid antigen detection test (RADT) and culture, and antibody titers were determined in serum samples. A range of case definitions were used for GAS pharyngitis. A total of 422 children 3-12 years old were enrolled (140, 141 and 141 were 3-5, 6-9 and 10-12 years of age, respectively). The overall prevalence of GAS colonization during the study was 48%. Baseline antistreptolysin O, anti-DNaseB and anti-SCP antibody titers were higher for children older than 5 years. The incidence of GAS pharyngitis per 100 person-years was 15.9 for RADT/culture-proven and 4.6 for serologically confirmed pharyngitis. GAS throat colonization and pharyngitis were frequent in children 3-12 years old. The case definition employed impacted the measured incidence of GAS pharyngitis, with higher rates detected using RADT/culture-based definitions. These data suggest that case definition is important and that young children are exposed to GAS, which may inform plans for vaccine development and implementation.
Sections du résumé
BACKGROUND
Group A streptococci (GAS) are a major cause of pharyngitis in children. Recently, there were severe GAS outbreaks. The aims of this study were to assess pharyngeal colonization prevalence in healthy children, to assess different diagnostic definitions for GAS pharyngitis and to estimate incidence rates for these infections.
METHODS
A 2-year longitudinal study was conducted in healthy children in the United States. Pharyngeal swabs were cultured every 3 months for GAS colonization. Serum antistreptolysin O, antideoxyribonuclease B (DNaseB) and antistreptococcal C5a peptidase (SCP) antibody titers were assessed at baseline. When participants developed a sore throat, pharyngeal swabs were collected for rapid antigen detection test (RADT) and culture, and antibody titers were determined in serum samples. A range of case definitions were used for GAS pharyngitis.
RESULTS
A total of 422 children 3-12 years old were enrolled (140, 141 and 141 were 3-5, 6-9 and 10-12 years of age, respectively). The overall prevalence of GAS colonization during the study was 48%. Baseline antistreptolysin O, anti-DNaseB and anti-SCP antibody titers were higher for children older than 5 years. The incidence of GAS pharyngitis per 100 person-years was 15.9 for RADT/culture-proven and 4.6 for serologically confirmed pharyngitis.
CONCLUSIONS
GAS throat colonization and pharyngitis were frequent in children 3-12 years old. The case definition employed impacted the measured incidence of GAS pharyngitis, with higher rates detected using RADT/culture-based definitions. These data suggest that case definition is important and that young children are exposed to GAS, which may inform plans for vaccine development and implementation.
Identifiants
pubmed: 37768176
doi: 10.1097/INF.0000000000004111
pii: 00006454-202312000-00004
pmc: PMC10629608
doi:
Substances chimiques
Antistreptolysin
9006-92-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1045-1050Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Shaikh N, Leonard E, Martin JM. Prevalence of streptococcal pharyngitis and streptococcal carriage in children: a meta-analysis. Pediatrics. 2010;126:e557–e564.
Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55:1279–1282.
Danchin MH, Rogers S, Kelpie L, et al. Burden of acute sore throat and group A streptococcal pharyngitis in school-aged children and their families in Australia. Pediatrics. 2007;120:950–957.
Linder JA, Bates DW, Lee GM, et al. Antibiotic treatment of children with sore throat. JAMA. 2005;294:2315–2322.
Dooling KL, Shapiro DJ, Van Beneden C, et al. Overprescribing and inappropriate antibiotic selection for children with pharyngitis in the United States, 1997-2010. JAMA Pediatr. 2014;168:1073–1074.
Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010-2011. JAMA. 2016;315:1864–1873.
Bisno AL. Acute pharyngitis: etiology and diagnosis. Pediatrics. 1996;97(6 Pt 2):949–954.
Bisno AL. Acute pharyngitis. N Engl J Med. 2001;344:205–211.
Barnes M, Youngkin E, Zipprich J, et al. Notes from the field: increase in pediatric ivasive group A Streptococcus infections - Colorado and Minnesota, October-December 2022. MMWR Morb Mortal Wkly Rep. 2023;72:265–267.
World Health Organization. Increased incidence of scarlet fever and invasive Group A Streptococcus infection - multi-country. 2022. Available at: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON429 . Accessed May 15, 2023.
Carapetis JR, Steer AC, Mulholland EK, et al. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685–694.
de Dassel JL, Ralph AP, Carapetis JR. Controlling acute rheumatic fever and rheumatic heart disease in developing countries: are we getting closer? Curr Opin Pediatr. 2015;27:116–123.
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527–1534.
O’Loughlin RE, Roberson A, Cieslak PR, et al.; Active Bacterial Core Surveillance Team. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007;45:853–862.
Nelson GE, Pondo T, Toews KA, et al. Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012. Clin Infect Dis. 2016;63:478–486.
Sims Sanyahumbi A, Colquhoun S, Wyber R, et al. Global disease burden of group A streptococcus. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City, OK: The University of Oklahoma Health Sciences Center; 2016.
Cannon JW, Jack S, Wu Y, et al. An economic case for a vaccine to prevent group A streptococcus skin infections. Vaccine. 2018;36:6968–6978.
Hughes GJ, van Hoek AJ, Sriskandan S, et al. The cost of hospital care for management of invasive group A streptococcal infections in England. Epidemiol Infect. 2015;143:1719–1730.
Pfoh E, Wessels MR, Goldmann D, et al. Burden and economic cost of group A streptococcal pharyngitis. Pediatrics. 2008;121:229–234.
Aboulhosn A, Sanson MA, Vega LA, et al. Increases in group A streptococcal infections in the pediatric population in Houston, TX, 2022. Clin Infect Dis. 2023;77:351–354.
de Gier B, Marchal N, de Beer-Schuurman I, et al.; ISIS-AR Study Group. Increase in invasive group A streptococcal ( Streptococcus pyogenes ) infections (iGAS) in young children in the Netherlands, 2022. Euro Surveill. 2023;28:2200941.
Guy R, Henderson KL, Coelho J, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. Euro Surveill. 2023;28:2200942.
Lassoued Y, Assad Z, Ouldali N, et al. Unexpected increase in invasive group A streptococcal infections in children after respiratory viruses outbreak in France: a 15-year time-series analysis. Open Forum Infect Dis. 2023;10:ofad188.
Shulman ST, Tanz RR, Gerber MA. Streptococcal pharyngitis. In: Stevens DL, Kaplan EL, eds. Streptococcal infections: Clinical aspects, microbiology, and molecular pathogenesis. Oxford University Press; 2000:76–101.
Johnson DR, Kurlan R, Leckman J, et al. The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. Clin Infect Dis. 2010;50:481–490.
Steer AC, Vidmar S, Ritika R, et al. Normal ranges of streptococcal antibody titers are similar whether streptococci are endemic to the setting or not. Clin Vaccine Immunol. 2009;16:172–175.
Shet A, Kaplan EL, Johnson DR, et al. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis. 2003;188:809–817.
Steer AC, Carapetis JR, Dale JB, et al. Status of research and development of vaccines for Streptococcus pyogenes . Vaccine. 2016;34:2953–2958.
Marshall HS, Richmond P, Nissen M, et al. Group A streptococcal carriage and seroepidemiology in children up to 10 years of age in Australia. Pediatr Infect Dis J. 2015;34:831–838.
Dixon JR Jr. The international conference on harmonization good clinical Practice guideline. Qual Assur. 1998;6:65–74.
Vijayananthan A, Nawawi O. The importance of good clinical practice guidelines and its role in clinical trials. Biomed Imaging Interv J. 2008;4:e5.
Bisno AL, Gerber MA, Gwaltney JM Jr, et al.; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis. 2002;35:113–125.
Centor RM, Witherspoon JM, Dalton HP, et al. The diagnosis of strep throat in adults in the emergency room. Med Decis Making. 1981;1:239–246.
Miller KM, Tanz RR, Shulman ST, et al.; Strep A Vaccine Global Consortium (SAVAC) Burden of Disease Working Group. Standardization of epidemiological surveillance of group A streptococcal pharyngitis. Open Forum Infect Dis. 2022;9(Suppl 1):S5–S14.
Hysmith ND, Kaplan EL, Cleary PP, et al. Prospective longitudinal analysis of immune responses in pediatric subjects after pharyngeal acquisition of group A streptococci. J Pediatric Infect Dis Soc. 2017;6:187–196.